 FOXF1 is a transcription factor that plays a critical role in regulating the development and function of endothelial cells. It has been shown to be down-regulated in patients with idiopathic pulmonary fibrosis, IPF, leading to increased collagen deposition and inflammatory responses. This study suggests that targeting FOXF1 could be a potential therapeutic strategy for treating IPF. This article was authored by Fenhua Bien, Ying Wei Lan, Xu Yang Zhao, and others.